TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species–Dependent Cell Signaling Alterations
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2400212 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Ashok Silwal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Reactive Oxygen Species, Signal Transduction, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
The role of the most common TP53 single-nucleotide polymorphism (SNP) at codon 72, which encodes for proline (P72) or arginine (R72), in the regulation of the immune system has not yet been thoroughly explored. We found that this SNP contributes to aggravated inflammatory response in COVID-19 patients resulting from biased macrophage activation. R72-P53 inhibits mitochondrial manganese superoxide dismutase, leading to impaired reactive oxygen species scavenging, oxidation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and, consequently, its inhibition. Reduced PTEN activity causes constitutive activation of the PI3K/Akt pathway, which restricts proinflammatory (M1) and promotes anti-inflammatory (M2) phenotypes through NF-κB and p53 inhibition. In contrast, PTEN-reduced PI3K/Akt activity, in P72 carrying cells, favors M1 phenotypes. LPS-stimulated R72 macrophages fail to reduce tumor growth in a mouse model of cancer, in contrast with P72 macrophages, which preserve M1 phenotype in vivo and reduce tumor growth by enhancing antitumor T cell responses, consistent with antitumor functions of M1 macrophages. In addition, P72 macrophages contributed to increased mortality in a mouse model of LPS-induced endotoxemia. Therefore, given the high frequency of P72 in African Americans, cell signaling alterations driven by codon 72 of TP53 SNP may potentially contribute to differences in clinical outcomes and health disparities in common diseases associated with dysregulated macrophage activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.
- Research, Apellis Pharmaceuticals Inc., Waltham, MA.
- Discovery, Apellis Pharmaceuticals Inc., Waltham, MA.
- Department of Pharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.
ORCID-Profile: Ashok Silwal, Britney Reese, Bhaumik Patel, Yan Li, Ninh M La-Beck, Maciej M Markiewski
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
Zitieren
APA
Silwal, A., Reese, B., Patel, B., Li, Y., Kolev, M. V., La-Beck, N. M., Karbowniczek, M. M., & Markiewski, M. M. (2024). TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species–Dependent Cell Signaling Alterations. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2400212
Vancouver
Silwal A, Reese B, Patel B, Li Y, Kolev MV, La-Beck NM, et al. TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species–Dependent Cell Signaling Alterations. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2400212
BibTeX
@article{Silwal2024,
author = {Silwal, Ashok and Reese, Britney and Patel, Bhaumik and Li, Yan and Kolev, Martin V and La-Beck, Ninh M and Karbowniczek, Magdalena M and Markiewski, Maciej M},
title = {TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species–Dependent Cell Signaling Alterations},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2400212}
}
EUVIMED